Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

IntroductionDespite high cure rates with standard treatment, 30% patients with Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell transplantation (HCT) is considered standard of care. Brentuximab Vedotin (Bv) in combination with B...

Full description

Bibliographic Details
Main Authors: Vivek S. Radhakrishnan, Rajat Bajaj, Vasundhara Raina, Jeevan Kumar, Saurabh J. Bhave, Reghu K. Sukumaran Nair, Arijit Nag, Indu Arun, Lateef Zameer, Debdeep Dey, Neeraj Arora, Mayur Parihar, Jayanta Das, Rimpa B. Achari, Deepak K. Mishra, Mammen Chandy, Reena Nair
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
Hodgkin lymphoma
relapsed/refractory
Brentuximab vedotin (Adcetris) ®
bendamustine
transplantation
real world data (RWD)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.796270/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.796270/full

Similar Items